I agree that this site is using cookies. You can find further informations here.
X
Rixe, Olivier
84  results:
Search for persons X
?
1

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylate..:

Coveler, Andrew L ; Smith, David C ; Phillips, Tycel...
Journal for ImmunoTherapy of Cancer.  11 (2023)  6 - p. e005584 , 2023
Link: https://doi.org/10.1136/..
 
?
2

Phase IB Study of GITR Agonist Antibody TRX518 Singly and i..:

Davar, Diwakar ; Zappasodi, Roberta ; Wang, Hong...
Clinical Cancer Research.  28 (2022)  18 - p. 3990-4002 , 2022
Link: https://doi.org/10.1158/..
 
?
3

EPEN-14. A Phase 1, Safety and Dose Escalation Study of BXQ..:

Rixe, Olivier ; Morris, John ; Wesolowski, Robert...
Neuro-Oncology.  24 (2022)  Supplement_1 - p. i41-i41 , 2022
Link: https://doi.org/10.1093/..
 
?
4

RNAseq correlative biomarkers IFIT1B and VSTM5 predict prog..:

Adams, Sarah ; Muller, Carolyn ; O'Malley, David...
Gynecologic Oncology.  166 (2022)  - p. S60-S61 , 2022
Link: https://doi.org/10.1016/..
 
?
5

Mogamulizumab in Combination with Nivolumab in a Phase I/II..:

Hong, David S. ; Rixe, Olivier ; Chiu, Vi K....
Clinical Cancer Research.  28 (2021)  3 - p. 479-488 , 2021
Link: https://doi.org/10.1158/..
 
?
6

Phase II trial of the IDO pathway inhibitor indoximod plus ..:

Zakharia, Yousef ; McWilliams, Robert R ; Rixe, Olivier...
Journal for ImmunoTherapy of Cancer.  9 (2021)  6 - p. e002057 , 2021
Link: https://doi.org/10.1136/..
 
?
7

CTIM-05. A PHASE 1/2 STUDY OF THE COMBINATION OF INDOXIMOD ..:

Lukas, Rimas ; Phuphanich, Surasak ; Rudnick, Jeremy...
Neuro-Oncology.  23 (2021)  Supplement_6 - p. vi50-vi50 , 2021
Link: https://doi.org/10.1093/..
 
?
8

Assessment of effects of repeated oral doses of fedratinib ..:

Ogasawara, Ken ; LoRusso, Patricia M. ; Olszanski, Anthony J....
Cancer Chemotherapy and Pharmacology.  86 (2020)  1 - p. 87-95 , 2020
Link: https://doi.org/10.1007/..
 
?
9

A phase 1 study of PF-06840003, an oral indoleamine 2,3-dio..:

Reardon, David A. ; Desjardins, Annick ; Rixe, Olivier...
Investigational New Drugs.  38 (2020)  6 - p. 1784-1795 , 2020
Link: https://doi.org/10.1007/..
 
?
10

Precision Oncology for Cancer Immunotherapies in Early-Phas..:

Paliard, Xavier ; Rixe, Olivier
Targeted Oncology.  14 (2019)  6 - p. 631-637 , 2019
Link: https://doi.org/10.1007/..
 
?
11

NIMG-22. HIGH-GRADE GLIOMA OUTCOMES IN THE PHASE 1 BXQ-350 ..:

Puduvalli, Vinay ; Villano, John ; Wise-Draper, Trisha...
Neuro-Oncology.  20 (2018)  suppl_6 - p. vi180-vi180 , 2018
Link: https://doi.org/10.1093/..
 
?
12

Alpha-Emitters and Targeted Alpha Therapy in Oncology: from..:

Makvandi, Mehran ; Dupis, Edouard ; Engle, Jonathan W....
Targeted Oncology.  13 (2018)  2 - p. 189-203 , 2018
Link: https://doi.org/10.1007/..
 
?
13

RARE-10. INITIAL EXPERIENCE IN EPENDYMOMA WITH INVESTIGATIO..:

Puduvalli, Vinay ; Villano, John ; Wise-Draper, Trisha...
Neuro-Oncology.  20 (2018)  suppl_6 - p. vi238-vi238 , 2018
Link: https://doi.org/10.1093/..
 
?
14

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib..:

Wise-Draper, Trisha M. ; Moorthy, Ganesh ; Salkeni, Mohamad A....
Targeted Oncology.  12 (2017)  3 - p. 323-332 , 2017
Link: https://doi.org/10.1007/..
 
?
15

ATIM-29. A PHASE 1 STUDY OF PF-06840003, AN ORAL INDOLE 2,3..:

Reardon, David ; Desjardins, Annick ; Rixe, Olivier...
Neuro-Oncology.  19 (2017)  suppl_6 - p. vi32-vi32 , 2017
Link: https://doi.org/10.1093/..
 
1-15